(Q41636119)

5 October 2017

title

Safety and immunogenicity of dry powder measles vaccine administered by inhalation: a randomized controlled Phase I clinical trial (English)

1 reference

5 October 2017

main subject

phase I clinical trial

0 references

1 reference

17

Paul A Rota

1 reference

5 October 2017

MVDP author group

1

1 reference

5 October 2017

Stephen Cape

2

1 reference

5 October 2017

Amol Chaudhari

3

1 reference

5 October 2017

Vivek Vaidya

4

1 reference

5 October 2017

Ravindra Mulay

5

1 reference

5 October 2017

Shalaka Agarkhedkar

6

1 reference

5 October 2017

Charles Shermer

7

1 reference

5 October 2017

Marcus Collins

8

1 reference

5 October 2017

Raydel Anderson

9

1 reference

5 October 2017

Sharad Agarkhedkar

10

1 reference

5 October 2017

Prasad S Kulkarni

11

1 reference

5 October 2017

Scott Winston

12

1 reference

5 October 2017

Robert Sievers

13

1 reference

5 October 2017

Rajeev M Dhere

14

1 reference

5 October 2017

Bhagwat Gunale

15

1 reference

5 October 2017

Ken Powell

16

1 reference

5 October 2017

Mark Papania

18

1 reference

5 October 2017

language of work or name

English

0 references

publication date

22 October 2014

1 reference

5 October 2017

1 reference

5 October 2017

volume

32

1 reference

5 October 2017

issue

50

1 reference

5 October 2017

page(s)

6791-6797

1 reference

The clinical significance of measles: a review

5 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Case-fatality rate during a measles outbreak in eastern Niger in 2003.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Increasing the time of exposure to aerosol measles vaccine elicits an immune response equivalent to that seen in 9-month-old Mexican children given the same dose subcutaneously

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Evaluation of immunogenicity and side effects of triple viral vaccine (MMR) in adults, given by two routes: subcutaneous and respiratory (aerosol).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: Comparisons with injected MMR

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Safety and Antibody Responses to Aerosolized MMR II Vaccine in Adults: An Exploratory Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

A new, rapid, and promising approach to aerosol immunization: inflatable bags and valved masks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Booster immune response in children 6-7 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Stabilization of measles virus for vaccine formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Dry powder measles vaccine: particle deposition, virus replication, and immune response in cotton rats following inhalation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Preparation of active proteins, vaccines and pharmaceuticals as fine powders using supercritical or near-critical fluids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Measles antibody: reevaluation of protective titers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Research priorities for global measles and rubella control and eradication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Aerosolized MMR vaccine: Evaluating potential transmission of components to vaccine administrators and contacts of vaccinees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

Measles vaccination of macaques by dry powder inhalation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.09.071

10.1016/J.VACCINE.2014.09.071

7 January 2021

Identifiers

DOI

1 reference

5 October 2017

1 reference